REGENXBIO Inc.

RGNX | NASDAQ

Price Alert Chart Builder DCF Calculator

$7.88

-$0.15 (-1.87%)

At close: Sep 21, 2026, 4:00 PM ET

$7.88

$0 (0.00%)

After-hours: Sep 21, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-1.87%

(1D)

Rating

Updated: Aug 14, 2026

40.5

Fundamentals Weak

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $407.38M

1D Range

7.76 8.20

52W Range

5.46 16.19

Valuation (TTM)

PE -2.08

PB 5.68

EV/EBITDA -2.67

Valuation (NTM)

Forward PE N/A

Forward PEG 0.16

Price Target $19.60

Cash Flow

FCF Yield -80.3%

SBC Adj. FCF Yield -91.0%

SBC Impact -13.4%

Margins

Gross Margin 54.2%

Operating Margin -94.1%

FCF Margin -187.5%

Growth (CAGR)

Revenue 3Y | 5Y 21.6% | 1.6%

Dil EPS 3Y | 5Y 17.8% | -24.6%

FCF 3Y | 5Y -32.4% | -49.9%

Returns

ROA -50.8%

ROE -220.1%

ROIC -52.7%

Financial Health

Net Cash

$36.57M

Current Ratio 2.86

Interest Coverage -3.91

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to...

Sector Healthcare

Industry Biotechnology

Employees 371

IPO Date Sep 16, 2015

Website www.regenxbio.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 5, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$18

Upside

+128.43%

Buy (8)

Hold (1)

Sell (0)

Analyst Details ➞